Auron Therapeutics begins patient dosing in phase 1 trial of AUTX-703 in advanced hematologic malignancies: Newton, Massachusetts Monday, June 2, 2025, 16:00 Hrs [IST] Auron Thera ...

The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel ...

A novel triple reuptake inhibitor is efficacious and ‘clinically meaningful’ for adult attention-deficit/hyperactivity ...

The findings suggest that "the heightened focus on alternative endpoints, now representing the most common primary endpoint, ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

UC Davis Comprehensive Cancer Center is testing a drug called niraparib (ZEJULA), given before prostate cancer surgery.

One in five patients (21.9%) participated in one or more cancer clinical research studies. In a first-time use of national accreditation information from the CoC, enrollment to cancer treatment trials ...

The trial focused on a drug called Duavee, a combination of conjugated estrogens and bazedoxifene, which is already approved ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...